247 related articles for article (PubMed ID: 17582943)
1. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R
Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943
[TBL] [Abstract][Full Text] [Related]
2. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
3. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
[TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
[TBL] [Abstract][Full Text] [Related]
9. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
Vantelon JM; Koscielny S; Brault P; Bourhis JH; Ribrag V; Pico J; Fenaux P; Munck JN
Bone Marrow Transplant; 2000 Mar; 25(5):495-9. PubMed ID: 10713625
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
11. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
12. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
13. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics of blood cells during peripheral blood stem cell mobilization following chemotherapy in patients with non-Hodgkin's lymphoma].
Okada Y; Ando M; Kato T; Taji H; Kagami Y; Ogura M; Morishima Y
Rinsho Ketsueki; 2000 Feb; 41(2):91-6. PubMed ID: 10723236
[TBL] [Abstract][Full Text] [Related]
17. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
[TBL] [Abstract][Full Text] [Related]
18. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment.
Milone G; Leotta S; Indelicato F; Mercurio S; Moschetti G; Di Raimondo F; Tornello A; Consoli U; Guido G; Giustolisi R
Bone Marrow Transplant; 2003 May; 31(9):747-54. PubMed ID: 12732880
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
20. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
